Focus: MicroPort is a Shanghai-based medical device manufacturer founded in 1998, specializing in cardiovascular, neurology, and orthopedic device solutions with a diversified portfolio of branded products.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow MicroPort to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship sirolimus-eluting stent platform with multiple variants addressing coronary disease; core revenue driver for cardiovascular segment.
Help build intelligence for MicroPort
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MicroPort's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Transcatheter aortic valve replacement system addressing high-prevalence structural heart disease with multiple generation iterations.
Broad femoral stem portfolio for total hip arthroplasty covering multiple surgical approaches and patient anatomies.
Advanced total knee arthroplasty system with medial pivot design and robotic-assisted surgical options; orthopedic growth driver.
Flow-diverter stent for intracranial aneurysm treatment representing MicroPort's neurology platform expansion.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 3 crawl cycles